Leroy Merlin Enriches the Customer Experience With Hanshow Digital Solutions
7.6.2024 11:30:00 EEST | Business Wire | Press release
Hanshow, a leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Leroy Merlin, a global DIY leader, have partnered to enhance customer and employee experiences by deploying ESLs across over 50,000 products integrated with the Leroy Merlin mobile app in France. Customers now enjoy seamless shopping with easy product geolocation and personalized recommendations in Leroy Merlin stores. After 18 months of R&D, they implemented a fully customized solution in all Leroy Merlin outlets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604438443/en/
Hanshow's ESL Solution at Leroy Merlin. (Graphic: Business Wire)
Enhanced Customer Support with Leroy Merlin's Mobile Application
This immersive experience is powered by the Leroy Merlin mobile application in conjunction with Hanshow's state-of-the-art ESL solutions. Leroy Merlin’s integration of Hanshow ESL into its app offers geolocation in-store to guide customers to products and aisles. This enhances the shopping experience and allows staff to provide more personalized advice and support.
The ESL solution also provides price consistency between online and offline channels, enriching user experience with various features such as customer reviews, enriched product descriptions, access the Home Index to assess a product's environmental and social impact, and the ability to flash labels directly from the application. These functions provide flexibility for consumers and store associates.
"We have successfully met the expectations of Leroy Merlin customers by developing a solution that enhances the in-store experience. By combining data and technological innovations, we have created a tailor-made tool that delivers a personalized experience for each customer," explains Pierre Fosseux, VP of Hanshow France.
Enhancing Retail Efficiency and Customer Experience
Whether it's stock management, restocking, or click-and-collect order preparation, the geolocation of products in the shop is a real time-saver for staff, who can devote themselves to focusing on higher-value tasks. "It now takes sales staff around 75 seconds to pick up a product, instead of 90 seconds previously, for orders placed online and picked up in the shop within a two-hour window chosen by the customer," says Olivier Personne, Merchandising Optimization Manager at Leroy Merlin. Eliminating price differences has positively improved customer satisfaction.
"The solution co-constructed with Hanshow enriches the customer experience across online and offline channels while simplifying in-store team tasks. Currently deployed in France, it is designed for larger-scale rollout in other Leroy Merlin locations," explains Hugues Hartung de la Roer, Concept & Merchandising Director at Leroy Merlin France.
Exemplifying both companies' commitment to enhancing customer satisfaction and driving innovation in the retail sector, the new solution not only simplifies the shopping process but also provides valuable data insights to improve store operations and customer engagement.
The collaboration won the Reta Awards 2024: Best In-store Solution for Leroy Merlin and Top Supplier for Hanshow, for transforming the retail environment with advanced technology.
About Leroy Merlin France
A pioneering company in the Adeo Group, Leroy Merlin is now the leading brand in France in all distribution channels for improving the home and the living environment. Specialising in the sale of products, projects and services, Leroy Merlin France has set itself the goal of building new ways of living with everyone, so that we can live better in the future, and puts customer satisfaction at the heart of its business.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions . The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604438443/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom